AMRA Medical

20/10/2026

From research roots in Linköping, Sweden to supporting pharmaceutical development globally.

Today, Dagens Industri features AMRA Medical, the journey behind our science, and where it is taking us next.

The article explores how the rapidly evolving obesity treatment landscape is creating new demand for better ways to understand changes in muscle and fat during weight loss, and how AMRA’s technology is helping generate deeper insights into these changes positively impacting patient care.

It also looks at AMRA’s broader journey — from research and innovation in Linköping to applying our science across pharmaceutical development and, increasingly, clinical care.

Read the full interview with our CEO, Olof Dahlqvist Leinhard, here:

LINKÖPING. Viktminskningsläkemedlen ska få kilona att försvinna. Men vad händer med musklerna? Den frågan har blivit en växande affär för Amra Medical.

26/09/2026

Today, Team AMRA is joining the FSHD Society’s Walk & Roll to Cure FSHD!

Members of our team are walking alongside the FSHD community in two U.S. cities:

📍 St. Louis, MO — September 26
📍 Worcester, MA — September 27

Since launching in 2018, Walk & Roll has grown into a powerful movement bringing communities together to raise awareness, advance research, and support individuals and families living with FSHD.

As a Silver Sponsor, AMRA is proud to support this year’s initiative, and even prouder to have our team there in person walking, connecting, and standing alongside the FSHD community.

Come find us and say hello!

17/09/2026

We’re proud to share some exciting news: AMRA Medical has once again been named one of the world’s leading HealthTech companies by TIME and Statista — this year earning an Outstanding ranking, the highest distinction, in the Diagnostics category.

This reflects our continued leadership in advanced MRI-based analysis of fat distribution and muscle composition — transforming medical images into standardized, quantitative insights that support research, drug development and an evolving role in healthcare.

For us, the recognition reinforces something that has guided AMRA from the beginning: there is far more to understand about human health than what we can see from the outside.

That’s why we continue to look deeper.
Insights Within.

Read more: https://amramedical.com/amra-medical-earns-times-highest-outstanding-rating-in-worlds-top-healthtech-companies-2026/

14/09/2026

A major milestone for AMRA Medical — and an important step in our next phase of global growth.

We’re pleased to announce an investment from HealthCap, one of Europe’s leading life science venture capital firms.

The investment will support AMRA’s continued product innovation and international expansion as we work to meet growing demand for precise, scalable advanced muscle and fat imaging across clinical research and healthcare.

With HealthCap’s deep life sciences expertise and global network, we’re well positioned to build on more than 15 years of scientific research and bring AMRA’s quantitative MRI technology to broader applications worldwide.

Read the full announcement: https://amramedical.com/healthcap-invests-in-amra-medical-to-accelerate-global-growth-in-quantitative-mri/

26/08/2026

Featured on the cover of Neurology.

New research using AMRA® Researcher published in Neurology as “Muscle MRI as an imaging biomarker of muscle damage in patients with spinal and bulbar muscular atrophy” demonstrates the potential of quantitative whole-body MRI to measure changes in muscle composition during disease progression in Spinal and Bulbar Muscular Atrophy (SBMA)—and has been selected for the cover of Neurology.

In the study, MRI-derived muscle composition measures detected significant changes over 12 months, illustrating their responsiveness to disease-related muscle changes. Baseline MRI measures were also correlated with established clinical assessments, including SBMAFRS and the 2-Minute Walk Test.

The findings add to the growing evidence supporting quantitative MRI as a potential imaging biomarker in neuromuscular disease research, where the ability to detect changes in muscle compensation over time could help researchers better characterize disease progression and evaluate new therapies.

Congratulations to the researchers and collaborators behind this important work.

Read the Press Release here: https://amramedical.com/measuring-muscles-with-quantitative-mri-new-study-published-in-neurology-expands-the-evidence-for-using-mri-biomarkers-in-sbma/. Read the full publication: https://doi.org/10.1212/WNL.0000000000218309.

15/07/2026

Day One of the 4th Annual Obesity & Weight Loss Drug Development Summit has been a great start to what will be an exciting few days of discussions around the future of obesity drug development!

The conversation at this year's Summit is shifting decisively beyond weight reduction alone and towards therapies designed to preserve physical function, optimize body composition, and deliver durable outcomes across the lifespan.

A consistent theme: the field needs sharper ways to distinguish fat loss from lean mass preservation. That means pairing standardized fat distribution and muscle composition metrics with functional endpoints such as mobility and strength, so trials capture not just changes in weight, but the quality of weight loss.

This morning, AMRA's CEO Olof Dahlqvist Leinhard took this discussion head-on in his Expert Partner presentation, "Reshaping the Standard: MRI Muscle Composition for Treatment Evaluation in Metabolic Disease and Beyond." He highlighted how standardized, validated MRI-based methods like those AMRA is developing are helping clinical development teams close the gap between muscle measurement and meaningful insights across a wide range of disease trials and populations.

As a Lead Partner this year, AMRA is proud to contribute to the conversations shaping the next generation of metabolic therapies and to bring that body of evidence to the teams designing them.
In Boston this week? We'd love to connect! Reach out to Leanna Kellerman or Olof Dahlqvist Leinhard onsite, via [email protected]

02/07/2026

The countdown to ICNMD 2026 is on!

Next week, AMRA Medical will be in picturesque Florence, Italy for the 19th International Congress on Neuromuscular Diseases (ICNMD).

During this year's congress, AMRA will present a poster featuring findings from the ReDUX4 Open-Label Extension study, exploring how quantitative whole-body MRI can provide sensitive, objective biomarkers for use in Facioscapulohumeral Muscular Dystrophy (FSHD) trials. The research highlights the potential of using standardized MRI-based muscle biomarkers to detect subtle changes over time, supporting the development of more responsive endpoints for clinical trials across a wide array of NMD trials.

As therapies continue to advance across the NMD landscape, reliable and sensitive biomarkers are becoming increasingly important for understanding disease progression and evaluating treatment response. We're proud to be a part of the NMD research community, working to advance quantitative MRI technologies that generate deeper insights and support the development of new therapies.

Will you be attending ICNMD? We'd love to connect!

Make sure to stop by our poster, titled “Responsiveness to change of quantitative whole-body MRI in FSHD: Results from ReDUX4 OLE” during the viewing sessions spanning the duration of the Congress.

Reach out to the AMRA team members Leanna Kellerman or Mary Foltz who are onsite via [email protected] to schedule a meeting. We look forward to seeing you in Florence!

24/06/2026

AMRA Medical is heading to Chicago for the 33rd International Research Congress on FSHD (IRC on FSHD), taking place June 25-26!

As a proud Bronze Sponsor of this year's meeting, AMRA will join researchers, clinicians, industry leaders, and patient advocates from across the global FSHD community to discuss the latest advances in Facioscapulohumeral Muscular Dystrophy (FSHD) research and therapeutic development.

This year, AMRA will share findings from three research efforts focused on the use of quantitative whole-body MRI biomarkers to better understand muscle changes in participants with FSHD. These studies highlight the potential of MRI-based biomarkers to detect subtle changes in muscle composition, which aid researchers in improving the sensitivity of clinical trials, and providing deeper insights into treatment effects over time.

Will you be attending IRC 2026? We would love to connect! Be sure to visit the Session 1: Biomarkers of Disease Activity and Progression poster sessions on Thursday, June 25th to learn more about our latest in FSHD research.

To schedule a time to discuss how AMRA can support your future goals in neuromuscular disease research and beyond, contact [email protected].

20/06/2026

Today, June 20th, marks World FSHD Day 🍊

Across our AMRA family worldwide, we’re showing our support for the FSHD community today with a simple orange-slice smile!

The orange slice smile is a symbol that reflects the recognition and support of the people living with Facioscapulohumeral Muscular Dystrophy (FSHD), which is a neuromuscular disease that can weaken the muscles that make it possible to smile. We also stand with their families, caregivers, and everyone dedicated to advancing research, care, and understanding of this disease on this worldwide day of recognition!

Many of us at AMRA have the privilege of working alongside those striving to make a difference in FSHD and other rare diseases. While there is still much to learn, we’re encouraged by the progress being made and grateful to play a role in supporting the research that helps move the field forward.

Today, we stand with the global FSHD community: celebrating resilience, recognizing the importance of continued research, and looking ahead with hope. Show us your Orange Slice Selfie below!

03/06/2026

Come Meet AMRA at ADA 2026!

We’re excited to be attending the 2026 American Diabetes Association (ADA) Scientific Sessions, taking place June 5–9 in New Orleans, Louisiana!

As the conversation around obesity, diabetes, and metabolic health in general continues to evolve and take center-stage globally, AMRA Medical remains at the forefront of delivering MRI-based biomarkers that provide deeper insights into fat distribution and muscle composition. We’re committed to supporting diabetes and metabolic trials by providing high-quality, reproducible data capable of capturing meaningful changes beyond conventional measures such as body weight or BMI.

If you’ll be attending ADA 2026, we’d love to start a conversation. Connect with our team members onsite via [email protected], and we’re looking forward to seeing you in New Orleans!